PGM3

phosphoglucomutase 3

Basic information

Region (hg38): 6:83147324-83193936

Links

ENSG00000013375NCBI:5238OMIM:172100HGNC:8907Uniprot:O95394AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • immunodeficiency 23 (Definitive), mode of inheritance: AR
  • immunodeficiency 23 (Strong), mode of inheritance: AR
  • immunodeficiency 23 (Supportive), mode of inheritance: AR
  • immunodeficiency 23 (Strong), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Immunodeficiency 23ARAllergy/Immunology/Infectious; OncologicIndividuals are susceptible to recurrent and severe viral, bacterial, and fungal infections (as well as sequelae such as EBV-related lymphoma), and and prophylaxis, as well as prompt and aggressive treatment of infections may be beneficialAllergy/Immunology/Infectious; Audiologic/Otolaryngologic; Craniofacial; Musculoskeletal; Neurologic; Oncologic14981714; 24589341; 24698316; 24931394

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the PGM3 gene.

  • Immunodeficiency_23 (520 variants)
  • Inborn_genetic_diseases (54 variants)
  • not_provided (30 variants)
  • not_specified (11 variants)
  • PGM3-related_disorder (11 variants)
  • Severe_combined_immunodeficiency_disease (9 variants)
  • Hyper-IgE_syndrome (3 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the PGM3 gene is commonly pathogenic or not. These statistics are base on transcript: NM_000015599.3. Only rare variants are included in the table.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

EffectPLPVUSLBBSum
synonymous
2
clinvar
158
clinvar
2
clinvar
162
missense
6
clinvar
4
clinvar
149
clinvar
10
clinvar
1
clinvar
170
nonsense
7
clinvar
4
clinvar
2
clinvar
13
start loss
0
frameshift
22
clinvar
7
clinvar
29
splice donor/acceptor (+/-2bp)
7
clinvar
1
clinvar
8
Total 35 22 154 168 3

Highest pathogenic variant AF is 0.0000278819

Loading clinvar variants...

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
PGM3protein_codingprotein_codingENST00000506587 1332787
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.00001461.001256940541257480.000215
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.512273010.7550.00001443718
Missense in Polyphen64123.770.517071499
Synonymous0.3561031080.9560.000005431087
Loss of Function3.121433.50.4180.00000179387

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0002990.000299
Ashkenazi Jewish0.0002990.000298
East Asian0.0001090.000109
Finnish0.00004620.0000462
European (Non-Finnish)0.0002470.000246
Middle Eastern0.0001090.000109
South Asian0.0004900.000392
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Catalyzes the conversion of GlcNAc-6-P into GlcNAc-1-P during the synthesis of uridine diphosphate/UDP-GlcNAc, a sugar nucleotide critical to multiple glycosylation pathways including protein N- and O-glycosylation. {ECO:0000303|PubMed:24589341, ECO:0000303|PubMed:24698316, ECO:0000303|PubMed:24931394}.;
Pathway
UDP-<i>N</i>-acetyl-D-galactosamine biosynthesis II;Amino sugar and nucleotide sugar metabolism - Homo sapiens (human);Sialuria or French Type Sialuria;Sialuria or French Type Sialuria;Amino Sugar Metabolism;G(M2)-Gangliosidosis: Variant B, Tay-sachs disease;Tay-Sachs Disease;Salla Disease/Infantile Sialic Acid Storage Disease;Glucuronidation;Aminosugars metabolism;Post-translational protein modification;Metabolism of proteins;UDP-<i>N</i>-acetyl-D-glucosamine biosynthesis II;Synthesis of UDP-N-acetyl-glucosamine;Synthesis of substrates in N-glycan biosythesis;Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein;Asparagine N-linked glycosylation (Consensus)

Recessive Scores

pRec
0.671

Intolerance Scores

loftool
0.794
rvis_EVS
-0.27
rvis_percentile_EVS
34.6

Haploinsufficiency Scores

pHI
0.644
hipred
Y
hipred_score
0.544
ghis
0.552

Essentials

essential_gene_CRISPR
E
essential_gene_CRISPR2
E
essential_gene_gene_trap
E
gene_indispensability_pred
N
gene_indispensability_score
0.136

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Pgm3
Phenotype
hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; immune system phenotype; renal/urinary system phenotype; digestive/alimentary phenotype; endocrine/exocrine gland phenotype;

Gene ontology

Biological process
carbohydrate metabolic process;glucosamine metabolic process;UDP-N-acetylglucosamine biosynthetic process;protein N-linked glycosylation;protein O-linked glycosylation;spermatogenesis;glucose 1-phosphate metabolic process;hemopoiesis
Cellular component
cellular_component;cytosol
Molecular function
magnesium ion binding;phosphoacetylglucosamine mutase activity;phosphoglucomutase activity